RYR2 and catecholaminergic polymorphic ventricular tachycardia: Stutzman et al. created four iPSC-CM lines of CPVT patients with RYR2 mutations, (p.(Phe13Leu), p.(Leu14Pro), p.(Arg15Pro) and p.(Arg176Gln)), and treated them with nadolol and flecainide.